Holen Sie sich die Stockscreener-App
6.97
10.15%
-0.86
Schlusskurs vom Vortag:
$7.83
Offen:
$7.83
24-Stunden-Volumen:
84,990
Relative Volume:
1.71
Marktkapitalisierung:
$25.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-55.84M
KGV:
-0.3961
EPS:
-17.5951
Netto-Cashflow:
$-49.61M
1W Leistung:
-22.95%
1M Leistung:
-33.13%
6M Leistung:
-48.39%
1J Leistung:
+1,285%
1-Tages-Spanne:
$6.40
$7.90
1-Wochen-Bereich:
$6.40
$10.71
52-Wochen-Spanne:
$0.39
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Firmenname
Nextcure Inc
Sektor
Branche
Telefon
240-399-4900
Adresse
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
7.035 | 28.28M | 0 | -55.84M | -49.61M | -17.60 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.19 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.62 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-03-05 | Hochstufung | Truist | Hold → Buy |
| 2021-01-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Herabstufung | SunTrust | Buy → Hold |
| 2020-06-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-03-24 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-02 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-05 | Eingeleitet | Needham | Buy |
| 2019-11-26 | Eingeleitet | BTIG Research | Buy |
| 2019-07-09 | Eingeleitet | BofA/Merrill | Buy |
| 2019-06-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Nextcure Inc Aktie (NXTC) Neueste Nachrichten
NextCure (NXTC) Plunges Over 22% as Selling Pressure IntensifiesStraddle Setup - Newser
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beat Amid No Revenue and Steep Stock DeclineRising Community Picks - Newser
NextCure Inc. (NXTC) Gains 5.75% as Biotech Stock Tests Resistance Near $10.71Bollinger Band - Newser
NextCure stock (US65343E1082): biotech shares in focus after China licensing deal for SIM0505 - AD HOC NEWS
NextCure (NXTC) Q1 2026 Earnings: $-1.87 EPS Surges Past $-2.15 EstimatesSocial Buy Zones - Newser
NextCure stock (US65343E1082): biotech shares react to recent strategic update and Nasdaq trading mo - AD HOC NEWS
SilverArc and Devesh Gandhi report 176,057 shares in NextCure (NXTC) - Stock Titan
TradingKey - TradingKey
Lucid Capital Markets initiates NextCure stock with buy on ADC pipeline By Investing.com - Investing.com South Africa
Lucid Capital Markets initiates NextCure stock with buy on ADC pipeline - Investing.com
Lucid Capital Initiates NextCure(NXTC.US) With Buy Rating, Announces Target Price $25 - Moomoo
NXTC (NextCure) earnings beat estimates by 67 percent, yet shares retreat despite EPS outperformance.Attention Driven Stocks - Newser
How NextCure (NXTC) maintains its competitive edge | Q4 2025: Profit Exceeds ViewsRevenue Inflection Point - Newser
NextCure | 10-Q: Quarterly report - Moomoo
NextCure 1Q Loss/Shr $1.87 >NXTC - Moomoo
NextCure | 10-Q: Q1 2026 Earnings Report - Moomoo
NextCure (NASDAQ: NXTC) narrows loss but warns on going-concern and funding needs - Stock Titan
NextCure | 8-K: NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
FDA Fast Track and narrower loss mark Q1 2026 for NextCure (NASDAQ: NXTC) - Stock Titan
NextCure maps June cancer data, says cash lasts into 2027 - Stock Titan
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Weekly Voice
Simcere entities disclose 9.4% stake in NextCure (NXTC) - Stock Titan
NextCure initiates dose optimization study for ovarian cancer drug - Investing.com
NextCure initiates dose optimization study for ovarian cancer drug By Investing.com - Investing.com Nigeria
Biotechnology company NextCure Inc. announced it is accelerating the progress of its R&D projects by expanding its clinical research center network to Canada and Europe. - Bitget
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - The Manila Times
NextCure moves ovarian cancer drug into dose testing before ASCO - Stock Titan
NXTC - Finviz
NextCure Inc expected to post a loss of $1.81 a shareEarnings Preview - TradingView
What capacity utilization NextCure (NXTC)? (-2.47%) 2026-04-27Crowd Consensus Signals - Newser
NextCure (NXTC) Stock Rejected Order (Smart Money Exits) 2026-04-24Top Analyst Picks - Newser
NextCure (NASDAQ: NXTC) plans 2026 meeting, auditor, pay and equity plan votes - Stock Titan
NextCure to present SIM0505 cancer drug data at ASCO meeting - Investing.com
NextCure to present SIM0505 cancer drug data at ASCO meeting By Investing.com - Investing.com South Africa
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 - The Manila Times
NextCure and Simcere Announce Presentation of Phase 1 Data for SIM0505 at ASCO 2026 - Quiver Quantitative
NextCure Inc stock (US65343E1082): Is its immunotherapy pipeline strong enough to unlock biotech ups - AD HOC NEWS
Ladenburg Thalmann Upgrades NextCure (NXTC) - MSN
NXTC Forecast, Price Target & Analyst Ratings | NEXTCURE INC (NASDAQ:NXTC) - ChartMill
Resistance Check: Will Argan Inc benefit from rate cutsPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
GUOCHUN INTERNATIONAL INC. Reports No Revenue and Material Weaknesses in Q3 2025 10-Q/A Filing - Minichart
Published on: 2026-04-09 04:19:51 - baoquankhu1.vn
Surprises Report: Is NextCure Inc stock good for income investorsNew Guidance & Safe Entry Trade Signal Reports - baoquankhu1.vn
FDA Gives Fast Track Status to SIM0505 in Platinum-Resistant Ovarian Cancer - CancerNetwork
Activity Recap: Is NextCure Inc a defensive stock2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Is NextCure (NXTC) Stock heavily shorted | Price at $12.10, Up 8.67%Time Weighted Price - Newser
Value Recap: How is NextCure Inc managing supply chain issues2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
NextCure Gets FDA Fast Track for SIM0505 in Ovarian Cancer - National Today
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - Bitget
FDA fast-tracks NextCure ovarian cancer drug ahead of ASCO data - Stock Titan
Resistance Check: Is NextCure Inc exposed to currency risksMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Finanzdaten der Nextcure Inc-Aktie (NXTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):